Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Quote. Real-time Euronext Paris - 06/11 11:35:27 am
3.988 EUR   +2.55%
06/03NOVACYT  : Launches Two New COVID-19 Tests
MT
06/03NOVACYT  : Launch of two new PCR COVID-19 assays
PU
05/31NOVACYT  : Monthly statement on outstanding equity shares and voting rights
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt S.A. ("Novacyt" or the "Company"): Coronavirus Test Update and Notification of Final Results

04/29/2020 | 02:01am EDT

Regulatory News:

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides an update on its polymerase chain reaction (PCR) test for COVID-19, developed by Primerdesign, the Company’s molecular diagnostics division based in the UK.

Sales

As of 28 April 2020, Primerdesign has sold, received orders for or has been contracted to deliver over £90 million (€103 million) of its COVID-19 test. This figure includes the contracted minimum amount of test orders from the recently signed supply agreement with the UK’s Department of Health and Social Care and initial orders received to date from the collaboration with AstraZeneca, GSK and the University of Cambridge.

Novacyt is now supplying its COVID-19 test to more than 100 countries and approvals for the test have recently been received from Malaysia and Ecuador. The Company continues to increase its sales level into the US market and is evaluating potential options to further expand its presence in this important market.

Manufacturing capacity

On 15 April 2020, Novacyt announced plans to increase manufacturing capacity to approximately eight million tests per month. The Company is on track with this scale-up and expects to achieve at least this level of output during June 2020. In addition, Novacyt has signed manufacturing partnership agreements with two further contract manufacturers based in the UK. This provides Novacyt with a total of six sub-contract manufacturers in addition to its own manufacturing sites in Southampton and Camberley, which provides greater contingency and the flexibility to scale-up its manufacturing outputs beyond eight million tests per month when necessary.

Research and development update

As announced on 15 April 2020, Novacyt has been working to address the current reported global shortfall in extraction reagents required to perform PCR testing through the development of a new extraction technology. This technology avoids the use of magnetic beads commonly used in the extraction process. The development of a new “direct-to-PCR” extraction method, Exsig™ Free, used prior to running the Company’s COVID-19 test, will therefore remove the need for scarce reagents used with magnetic beads and significantly reduces the number of extraction steps, allowing faster cycle times, higher throughputs and cost savings. The Directors believe this innovation should facilitate an increase in testing capacity for COVID-19, removing a current bottleneck in sample processing for laboratories. Development is progressing well and Novacyt is on track to launch this new extraction technology in May 2020.

Notification of 2019 final results

Due to a longer review process of the financial statements caused by COVID-19, the Company now intends to report its audited results for the year ended 31 December 2019 during the week commencing 11 May 2020.

Graham Mullis, Chief Executive Officer of Novacyt, commented:

“The visibility of the sales order book is transformational for the business and it is becoming increasingly clear that this exceptional demand for our COVID-19 test could continue for some months. As a result, we continue to ensure we have significant capacity and flexibility in the manufacturing of our COVID-19 test.

“I am proud that innovation remains at the heart of the business and the forthcoming launch of our Exsig™ Free extraction kit will address a significant market need to increase testing availability and throughput. This is a challenging time for Novacyt but the transformation of our financial performance and our position as a market leader in clinical diagnostics means we are confident in the long-term prospects of the business.”

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com


© Business Wire 2020
All news about NOVACYT
06/03NOVACYT  : Launches Two New COVID-19 Tests
MT
06/03NOVACYT  : Launch of two new PCR COVID-19 assays
PU
05/31NOVACYT  : Monthly statement on outstanding equity shares and voting rights
CO
05/26GLOBAL MARKETS LIVE : Amazon, Volkswagen, AstraZeneca, Aston Martin, Sony...
05/26NOVACYT  : Launch of VersaLab™ Portable
PU
05/26NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of VersaLab™ Portable
BU
05/21NOVACYT  : Government and Covid test supplier Novacyt row over £150m PCR contrac..
AQ
05/21NOVACYT  : DHSC Dispute Update
PU
05/21NOVACYT S.A. ("NOVACYT", THE "COMPAN : DHSC Dispute Update
BU
05/17LONDON STOCK EXCHANGE : Banks, industrial stocks drag FTSE 100 down; Diploma jum..
RE
More news
Financials
Sales 2020 312 M 377 M 377 M
Net income 2020 185 M 224 M 224 M
Net cash 2020 102 M 123 M 123 M
P/E ratio 2020 1,52x
Yield 2020 -
Capitalization 282 M 341 M 341 M
EV / Sales 2020 0,58x
EV / Sales 2021 0,38x
Nbr of Employees 110
Free-Float 99,2%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 4,90 €
Last Close Price 3,99 €
Spread / Highest target 42,9%
Spread / Average Target 22,9%
Spread / Lowest Target 2,81%
EPS Revisions
Managers and Directors
NameTitle
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
R. A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capitalization (M$)
NOVACYT-59.31%341
MODERNA, INC.109.49%87 874
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
LONZA GROUP AG16.32%54 656